Sampson, J. H., Achrol, A., Aghi, M. K., Bankiewicz, K., Bexon, M., Brem, S., … Butowski, N. A. (2020). MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Sampson, John H., Achal Achrol, Manish K. Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Jacob Brenner, et al. “MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Sampson JH, Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, et al. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Sampson, John H., et al. “MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Sampson JH, Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner AJ, Chandhasin C, Chowdhary SA, Coello M, Das S, Han SJ, Kesari S, Merchant F, Merchant N, Randazzo D, Vogelbaum MA, Vrionis F, Zabek M, Butowski NA. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. JOURNAL OF CLINICAL ONCOLOGY. 2020.